Adjuvant immunotherapy reduces relapse risk in resected or ablated hepatocellular cancer
Data from the IMbrave050 study show benefits of atezolizumab plus bevacizumab in terms of disease recurrence, but long-term data are needed
Cancer Control Principles
How to integrate the social determinants of health in cancer care
Increasing data show that they are indicators of inequitable environments which may negatively impact on cancer outcomes, but more efforts are needed to properly assess them in oncology
Pembrolizumab plus chemotherapy prolongs survival in pleural mesothelioma
In the IND227 trial, more pronounced benefits of the immunotherapy were observed in patients with non-epithelioid histology and regardless of PD-L1 status
Cancer Control Principles
A net-zero emission oncology is made by small actions
Green oriented practical tips encompass a reorganisation of waste disposal and pathology testing at single centres which may result in a reduction of the carbon footprint of cancer care globally
Dostarlimab shows preliminary but durable activity across multiple cancers
Promising data are reported for tumours with dMMR, MSI-H and rare POLE alterations, reinforcing the role of molecular testing for tissue-agnostic treatment
Adding atezolizumab to bevacizumab and chemotherapy improves outcomes in metastatic cervical cancer
Results from the BEATcc study strongly support the use of first-line combination therapy for R/M CC in all patients
Antibody–drug conjugates improve outcomes for patients with inoperable or metastatic breast cancer
Promising results reported for datopotamab deruxtecan and trastuzumab deruxtecan in HER2-non-amplified breast cancer
Amivantamab combination therapies emerge as new options for EGFR-mutated advanced NSCLC
Clinically meaningful improvements over standard care were observed in both first and second line, as reported in the MARIPOSA and MARIPOSA-2 phase III trials
Datopotamab deruxtecan met the PFS endpoint in previously treated NSCLC
The TROP2-directed ADC improved PFS with reduced toxicity compared with chemotherapy in the TROPION-Lung01 trial, but results are not practice-changing
177Lu-PSMA-617 improves rPFS in taxane-naïve metastatic castration-resistant prostate cancer
However, lack of OS benefit limits the clinical impact of the findings from the PSMAfore trial